LCM
HALO icon

Legato Capital Management’s Halozyme HALO Stock Holding History

Legato Capital Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,460
Closed -$935K – 759
2026
Q1 		$935K Buy
+14,460
New +$1.02M 0.09% 309
2024
Q4 		– Sell
-20,419
Closed -$1.17M – 590
2024
Q3 		$1.17M Buy
20,419
+5,806
+40% +$333K 0.14% 259
2024
Q2 		$765K Buy
+14,613
New +$641K 0.1% 327

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Legato Capital Management's HALO Position: Q2 2026 in Review

Legato Capital Management sold out of Halozyme (HALO) in Q2 2026, closing a stake of 14,460 shares — an estimated $935K sold.

Legato Capital Management first reported a position in HALO in Q2 2024 and held it in 3 quarters. The position peaked at $1.17M in Q3 2024. 672 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Legato Capital Management reported no remaining Halozyme position as of Q2 2026 after selling out during the quarter.
  • Legato Capital Management sold 14,460 Halozyme shares in Q2 2026, an estimated $935K.
  • Legato Capital Management first reported a position in Halozyme in Q2 2024 and held it in 3 quarters.
  • Legato Capital Management's Halozyme position peaked at $1.17M in Q3 2024.
  • 672 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.